Frankfurt
11.12.24
09:07 Uhr
0,006 Euro
-0,001
-8,33 %
-8,33 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN | 164 | ACCESSWIRE | Admission of New Ordinary Shares and New ISIN LONDON, UNITED KINGDOM / ACCESSWIRE / December 10, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical... ► Artikel lesen | |
| Di | Hemogenyx Pharmaceuticals announces share restructure | 4 | Investing.com | ||
| Mo | Hemogenyx Pharmaceuticals shareholders approve share restructure | 2 | Investing.com | ||
| Mo | Hemogenyx Pharma Plc - Result of Extraordinary General Meeting | - | RNS | ||
| Mo | Hemogenyx Pharmaceuticals PLC Announces Site Initiation Visit Completed | 100 | ACCESSWIRE | Hemogenyx Pharmaceuticals Successfully Completes the Site Initiation Visit of the First Clinical Site for Phase I Clinical Trial of HG-CT-1 LONDON, UNITED KINGDOM / ACCESSWIRE / December 9, 2024 / Hemogenyx... ► Artikel lesen | |
| Fr | Hemogenyx Pharmaceuticals PLC Announces CBR Macrophage Delivery Update | 190 | ACCESSWIRE | Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development LONDON, UK / ACCESSWIRE / December 6, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical... ► Artikel lesen | |
| 29.11. | Hemogenyx Pharma Plc - Total Voting Rights | - | RNS | ||
| HEMOGENYX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 22.11. | Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting | 320 | ACCESSWIRE | Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New Articles of Association LONDON, UK / ACCESSWIRE... ► Artikel lesen | |
| 22.11. | Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial | 222 | ACCESSWIRE | Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical... ► Artikel lesen | |
| 11.11. | Hemogenyx Pharmaceuticals PLC Announces Institutional Investment | 256 | ACCESSWIRE | Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx... ► Artikel lesen | |
| 30.10. | IN BRIEF: Hemogenyx to launch myeloid leukemia treatment phase 1 trial | - | Alliance News | ||
| 30.10. | Hemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial Opening | 131 | ACCESSWIRE | Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)... ► Artikel lesen | |
| 02.10. | Hemogenyx shares boosted by partner investment | 6 | Sharecast | ||
| 02.10. | Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC | 312 | ACCESSWIRE | Prevail Partners, LLC to invest again in Hemogenyx PharmaceuticalsPrevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical study LONDON, UNITED... ► Artikel lesen | |
| 27.09. | Hemogenyx Pharmaceuticals loss narrows amid reduced expenses | 1 | Alliance News | ||
| 27.09. | Hemogenyx Pharmaceuticals PLC Announces Half-year Report | 160 | ACCESSWIRE | LONDON, UNITED KINGDOM / ACCESSWIRE / September 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose... ► Artikel lesen | |
| 09.09. | Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson | 163 | ACCESSWIRE | LONDON, UNITED KINGDOM / ACCESSWIRE / September 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases... ► Artikel lesen | |
| 02.09. | Hemogenyx Pharmaceuticals PLC Announces CDX Development Update | 278 | ACCESSWIRE | CDX Development Update LONDON, UNITED KINGDOM / ACCESSWIRE / September 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)("Hemogenyx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| 28.08. | Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference | 180 | ACCESSWIRE | LONDON, UNITED KINGDOM / ACCESSWIRE / August 28, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is... ► Artikel lesen | |
| 29.07. | Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation | 277 | ACCESSWIRE | Presentation at Macrophage-Directed Therapies Summit LONDON, UNITED KINGDOM / ACCESSWIRE / July 29, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the... ► Artikel lesen |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 0,133 | -0,75 % | Innocan Pharma Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| WPD PHARMACEUTICALS | 0,003 | 0,00 % | CSE Bulletin: Suspensions - GameOn Entertainment Technologies Inc., WPD Pharmaceuticals Inc. | Toronto, Ontario--(Newsfile Corp. - le 6 décembre/December 2024) Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts... ► Artikel lesen | |
| MYDECINE INNOVATIONS GROUP | 0,001 | -50,00 % | Mydecine Innovations Group Inc - Mydecine Announces Filing of Q3 Financial Statements | Mydecine Innovations Group Inc - Mydecine Announces Filing of Q3 Financial Statements
PR Newswire
LONDON, United Kingdom, November 21
MYDECINE ANNOUNCES FILING OF Q3 FINANCIAL... ► Artikel lesen | |
| BELLROCK BRANDS | 0,028 | 0,00 % | CSE Bulletin: Delist - BellRock Brands Inc. (BRCK.U) | Toronto, Ontario--(Newsfile Corp. - le 14 juin/June 2024) - The common shares of BellRock Brands Inc. will be delisted from the CSE at market close today, June 14, 2024. BellRock Brands is currently... ► Artikel lesen | |
| BAYER | 20,105 | -0,89 % | BioNTech, Medigene und Bayer: Deutsche Biotech-Unternehmen revolutionieren die Krebstherapie | In der Onkologie stehen spannende neue Entwicklungen an: BioNTech wandelt sich vom Covid-19-Impfstoffhersteller zum Krebsmedikamenten-Spezialisten. Mit der Übernahme des chinesischen Unternehmens Biotheus... ► Artikel lesen | |
| MERCK KGAA | 143,85 | -0,55 % | S&P bestätigt Merck KGaAs "A/A-1"-Ratings - Ausblick stabil | DJ S&P bestätigt Merck KGaAs "A/A-1"-Ratings - Ausblick stabil
DOW JONES--Die Ratingagentur S&P hat die Bonitätseinstufung der Merck KGaA mit "A/A-1" bestätigt. Der stabile Rating-Ausblick ist... ► Artikel lesen | |
| NOVO NORDISK | 105,24 | +1,29 % | Novo Nordisk übernimmt Novavax-Produktionsanlage in Tschechien | Novavax hat eine Vereinbarung über den Verkauf seiner hochmodernen Produktionsanlage in Bohumil, Tschechien, an Novo Nordisk geschlossen. Der Kaufpreis beträgt 200 Millionen US-Dollar, davon 190 Millionen... ► Artikel lesen | |
| MERCK & CO | 96,10 | 0,00 % | Merck & Co., Inc.: Merck Earns Top Spot on Newsweek's List of America's Most Responsible Companies 2025 | RAHWAY, NJ / ACCESSWIRE / December 5, 2024 / Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has ranked No. 1 on Newsweek's annual list of America's Most Responsible Companies... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 2,440 | 0,00 % | Cumberland Pharmaceuticals Inc.: FDA Approves Acetadote sNDA | - New Dosing Regimen Simplifies Administration -
NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty... ► Artikel lesen | |
| ELI LILLY | 755,70 | -0,62 % | Adipositas-Duell: Eli Lilly beeindruckt - diese Studiendaten setzen Novo Nordisk unter Druck | Im Duell zwischen den beiden Adipositas-Marktführern Eli Lilly und Novo Nordisk ist den Amerikanern ein weiterer Punktgewinn gelungen. Studiendaten zeigten, dass Zepbound von Eli Lilly bei der Gewichtsabnahme... ► Artikel lesen | |
| PFIZER | 24,315 | 0,00 % | Pfizer-Aktie auf Abwegen: Patentabläufe und schwächelnder Kurs | Die Aktie von Pfizer bleibt unter Druck. Nach starken Jahren während der Pandemie kämpft der Pharmariese mit sinkenden Umsätzen, Patentverlusten und einer skeptischen Anlegerbasis. Mit einem neuen Fokus... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 2,520 | 0,00 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| ASTRAZENECA | 128,25 | +0,27 % | GOLDMAN SACHS stuft ASTRAZENECA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca mit einem Kursziel von 15955 Pence auf "Buy" belassen. Die Daten einer weiteren Lungenkrebsstudie... ► Artikel lesen | |
| JUPITER NEUROSCIENCES | 9,590 | 0,00 % | Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering | Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the "Company" or "Jupiter Neurosciences"), a clinical stage pharmaceutical company advancing a pipeline... ► Artikel lesen | |
| GELTEQ | 4,410 | 0,00 % | Gelteq Limited Closes US$5.2 Million Initial Public Offering | NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible... ► Artikel lesen |
HEMOGENYX PHARMACEUTICALS PLC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,006 Euro und damit -8,33 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOGENYX PHARMACEUTICALS PLC finden Sie auf Wallstreet Online.
